1245.25.81014 Boehringer Ingelheim Investigational Site

Kumamoto-shi, Kumamoto

0 studies enrolling now · 1 studies all time

What they study most

Diabetes Mellitus, Type 2

Studies at this site

• BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). — Completed